Strategic Partnerships Draupnir Bio is a Denmark-based biotech spin-out merging academia and industry with ambitious extracellular and membrane-bound protein degradation work. This presents an opportunity to position complementary biotech and pharma partners (e.g., contract research, clinical development, and manufacturing collaborations) to accelerate development of their SORTAC platform and expand targeting capabilities.

Platform Commercialization The novel SORTAC platform enables extracellular protein degradation, a broad and high-potential addressable space. Sales conversations can focus on licensing, sponsored research, and collaboration deals to advance early programs, plus potential co-development models with pharma players seeking next-gen targeted protein degradation approaches.

Funding Leverage Recent and ongoing Danish and European funding includes Innovation Fund Denmark and Innovationsfonden investments, signaling market validation and strong grant-ready dynamics. Opportunities exist to support grant-backed collaborations, co-funding for translational activities, and leverage for joint grant proposals with potential partners.

Clinical & Access Focus Draupnir’s extracellular and membrane-targeted degraders imply novel therapy modalities with potentially improved oral small molecule formats. Sales discussions can explore early-access programs, regulatory strategy alignment, and partnering for clinical development and manufacturing to accelerate timelines to patients.

Global Ecosystem Fit With a Nordic-European leadership base and a track record of syndicate investor backing, Draupnir is positioned to attract CDMO, biotech accelerators, and regional partner networks. Target outreach can include joint ventures, technology licensing, and manufacturing collaborations to scale their lysosome-based degraders.